Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance
Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance.
調査の概要
詳細な説明
Residual depressive symptoms (RDS) following remission of major depressive disorder (MDD) are reported by 80-90% of adults receiving first-line antidepressant pharmacotherapy and carry an elevated risk for a chronic course of illness, rapid relapse and functional impairment. Strategies for managing residual symptoms, however, have met with mixed success. Mindful Mood Balance (MMB; R34 MH0877223) is an individually tailored, web-based treatment designed to train remitted depressed patients to disengage from dysphoria-activated depressogenic thinking that perpetuates RDS and increases risk for relapse/recurrence. MMB was developed to increase access to Mindfulness-Based Cognitive Therapy (MBCT; R01 MH066992), an empirically supported prophylactic group treatment that can be easily sequenced with acute phase antidepressant pharmacotherapy. Results from our open trial of MMB (N=100) showed an effect size of d=1.09 for pre to post treatment reductions in depression scores among patients with RDS and d=1.54 in a quasi-experimental comparison to patients receiving usual care, with an on average reduction of 1.98 points on the PHQ-9 for MMB patients. The investigators now propose a pragmatic randomized clinical trial of MMB to evaluate its effectiveness in reducing RDS in recurrently depressed patients. Patients will be members of Kaiser-Permanente Colorado (N = 460), aged 18 to 75, who score >5 and <9 on the PHQ-9, in remission from MDD and will be randomized 1:1 to either the usual depression care pathway (DepCare) or Mindful Mood Balance (MMB)+DepCare.
The investigators plan to test whether patients receiving MMB+DepCare will show greater reductions in RDS at both 8 week and 12 months follow up, than those receiving DepCare alone. The investigators are also interested in examining whether fewer patients in MMB+DepCare will relapse over the follow up and will have higher end state functioning and quality of life. In order to examine the costs associated with adding this online treatment to the Depression Care Pathways at KPCO, the investigators will calculate the marginal costs per additional number of depression free days (DFDs) for patients. Resolution of RDS can reduce the enormous personal and social costs experienced by Americans with this persistent symptom burden.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Colorado
-
Denver、Colorado、アメリカ、80237-8066
- Kaiser Permanente Institute for Health Research
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients with a PHQ-9 score between 5 and 9
- At least one prior episode of MDD
Exclusion Criteria:
- presence of schizophrenia or current psychosis, organic mental disorder or pervasive developmental delay
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Mindful Mood Balance
An 8 session internet intervention targeting residual depressive symptoms.
|
Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990).
Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
|
アクティブコンパレータ:Usual Depression Care
Usual Depression Care through Kaiser Permanente Colorado
|
Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Patient Health Questionnaire-9
時間枠:Change from Baseline to 12 weeks and 15 months
|
Changes in self reported depressive symptom severity
|
Change from Baseline to 12 weeks and 15 months
|
Patient Health Questionnaire-9
時間枠:Between 12 weeks and 15 months
|
Rates of depressive relapse, defined as patients who score 15 or greater on the PHQ-9
|
Between 12 weeks and 15 months
|
Patient Health Questionnaire-9
時間枠:Between baseline to 12 weeks.
|
Conversion from moderate/high risk to low risk symptom categories, defined as a patient whose PHQ-9 score drops from a baseline PHQ-9 score between 5 and 9 to a mean score of 4 or less
|
Between baseline to 12 weeks.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Ruminative Responses Scale
時間枠:Change from Baseline to 6 weeks, 12 weeks and 15 months
|
A self-report measure of rumination
|
Change from Baseline to 6 weeks, 12 weeks and 15 months
|
Five Facet Mindfulness Questionnaire
時間枠:Change from Baseline to 6 weeks, 12 weeks and 15 months
|
Self report measure of mindful awareness
|
Change from Baseline to 6 weeks, 12 weeks and 15 months
|
Five Facet Mindfulness Scale
時間枠:Change from Baseline to 6 weeks, 12 weeks and 15 months
|
Self report measure of mindful awareness
|
Change from Baseline to 6 weeks, 12 weeks and 15 months
|
Experiences Questionnaire
時間枠:Change from Baseline to 6 weeks, 12 weeks and 15 months
|
Self report measure of decentering/wider awareness
|
Change from Baseline to 6 weeks, 12 weeks and 15 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Depression Free Days
時間枠:Change from Baseline to 12 weeks and 15 months
|
Self report of days free of depression
|
Change from Baseline to 12 weeks and 15 months
|
Generalized Anxiety Disorder Assessment - 7
時間枠:Change from Baseline to 12 weeks and 15 months
|
Self report measure of generalized anxiety
|
Change from Baseline to 12 weeks and 15 months
|
Short Form Health Survey - 12
時間枠:Change from Baseline to 12 weeks and 15 months
|
Self report measure of physical and mental health
|
Change from Baseline to 12 weeks and 15 months
|
Emotion Dot Probe Task
時間枠:Change from Baseline to 12 weeks and 15 months
|
A behavioural measure of attentional bias
|
Change from Baseline to 12 weeks and 15 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Zindel V Segal, PhD、University of Toronto
出版物と役立つリンク
一般刊行物
- Boggs JM, Beck A, Felder JN, Dimidjian S, Metcalf CA, Segal ZV. Web-based intervention in mindfulness meditation for reducing residual depressive symptoms and relapse prophylaxis: a qualitative study. J Med Internet Res. 2014 Mar 24;16(3):e87. doi: 10.2196/jmir.3129.
- Segal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, Bloch R, Levitan RD. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry. 2010 Dec;67(12):1256-64. doi: 10.1001/archgenpsychiatry.2010.168.
- Dimidjian S, Beck A, Felder JN, Boggs JM, Gallop R, Segal ZV. Web-based Mindfulness-based Cognitive Therapy for reducing residual depressive symptoms: An open trial and quasi-experimental comparison to propensity score matched controls. Behav Res Ther. 2014 Dec;63:83-9. doi: 10.1016/j.brat.2014.09.004. Epub 2014 Sep 18.
- Boggs JM, Ritzwoller DP, Beck A, Dimidjian S, Segal ZV. Cost-Effectiveness of a Web-Based Program for Residual Depressive Symptoms: Mindful Mood Balance. Psychiatr Serv. 2022 Feb 1;73(2):158-164. doi: 10.1176/appi.ps.202000419. Epub 2021 Jul 29.
- Segal ZV, Dimidjian S, Beck A, Boggs JM, Vanderkruik R, Metcalf CA, Gallop R, Felder JN, Levy J. Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Jun 1;77(6):563-573. doi: 10.1001/jamapsychiatry.2019.4693. Erratum In: JAMA Psychiatry. 2020 May 1;77(5):545.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- R01MH102229-01A1 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Usual Depression Careの臨床試験
-
Massachusetts General HospitalNational Institutes of Health (NIH); Samaritans of Bostonまだ募集していません自殺念慮 | 自殺未遂 | 自殺
-
New York UniversityIndiana University; Moi University完了
-
New York UniversitySt. Luke's-Roosevelt Hospital Center完了
-
Fondation Lenval積極的、募集していない
-
Fondation Oeuvre de la Croix Saint-Simon引きこもった
-
Boston Medical CenterNational Institute on Minority Health and Health Disparities (NIMHD); Center for Community Health...完了肥満 | 喘息 | 血圧 | 小児発達 | ヘルスケアの利用 | 児童虐待 | 医療格差 | 満たされていない基本的な社会的ニーズアメリカ
-
Saint-Joseph University完了
-
University Health Network, Toronto募集リンパ腫 | リンパ増殖性疾患 | 乳がんステージ I | 乳がんステージ II | 大腸がんステージ II | 結腸直腸がん III期 | 乳がんステージ III | 結腸直腸がんステージ I | 頭頸部がん III期 | 乳がん、ステージ0 | 頭頸部がんステージ I | 頭頸部がんステージ IIカナダ